2m 2m 2m 2m 2m 2m 2m
DYNE THERAPEUTCS (DYN)
NASDAQ
$21.05+$0.18 (+0.84%)
Price as of Jun 23, 2026 9:34 AM EDT- $3.5BMarket Cap
- 105.41%1-Year Change
- BiotechnologyIndustry
DYNE THERAPEUTCS (DYN)
$21.05+$0.18 (+0.84%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cost of Revenue | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Gross Profit | 0 N/A | 0 N/A | 0 N/A | 0 N/A | |
Sales and Marketing Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Research and Development Expense | -398.3M +41.55% | -281.4M +33.52% | -210.8M +47.63% | -142.8M +17.68% | |
Depreciation and Amortization Expense | 2.0M +22.47% | 1.7M 0.00% | 1.7M -0.59% | 1.7M +54.69% | |
Total Operating Expenses | 468.2M +36.15% | 343.9M +42.01% | 242.2M +41.65% | 171.0M +13.96% | |
Operating Profit | -468.2M +36.15% | -343.9M +42.01% | -242.2M +41.65% | -171.0M +13.96% | |
Interest Income | 29.9M +10.91% | 26.9M +252.34% | 7.6M +161.95% | 2.9M +293.13% | |
Interest Expense | -6.2M N/A | N/A N/A | N/A N/A | N/A N/A | |
Interest Income and Expense and Net | 23.7M -12.09% | 26.9M +252.34% | 7.6M +161.95% | 2.9M +293.13% | |
Total Nonoperating Income and Expense | 22.0M -16.99% | 26.5M +325.19% | 6.2M +117.43% | 2.9M +290.05% | |
Income before Taxes | -468.2M +36.15% | -343.9M +42.01% | -242.2M +41.65% | -171.0M +13.96% | |
Income Taxes | 0 N/A | N/A N/A | N/A N/A | N/A N/A | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | -446.2M +40.58% | -317.4M +34.54% | -235.9M +40.36% | -168.1M +12.60% | |
Net Income from Continuing Operations Applicable to Common | -446.2M +40.58% | -317.4M +34.54% | -235.9M +40.36% | -168.1M +12.60% | |
Basic EPS and Net Income | -3.47 +2.97% | -3.37 -14.68% | -3.95 +22.29% | -3.23 +10.24% | |
Diluted EPS and Net Income | -3.47 +2.97% | -3.37 -14.68% | -3.95 +22.29% | -3.23 +10.24% | |
Basic Weighted Average Shares | 128.4M +36.43% | 94.1M +57.74% | 59.7M +14.83% | 52.0M +2.12% | |
Diluted Weighted Average Shares | 128.4M +36.43% | 94.1M +57.74% | 59.7M +14.83% | 52.0M +2.12% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 893.4M +105.16% | 435.4M +258.02% | 121.6M -29.35% | 172.1M -14.28% | |
Short-Term Investments | 217.2M +5.02% | 206.8M +13,931.14% | 1.5M -98.24% | 83.9M -52.28% | |
Cash and Cash Equivalents and Short-Term Investments | 1.1B +72.91% | 642.3M +421.74% | 123.1M -51.92% | 256.0M -32.01% | |
Total Current Assets | 1.1B +70.88% | 659.3M +409.59% | 129.4M -51.29% | 265.6M -30.54% | |
Accumulated Depreciation | 8.7M +28.76% | 6.8M +28.08% | 5.3M +45.72% | 3.6M +83.01% | |
Property and Plant and Equipment and Net | 24.0M +345.15% | 5.4M +12.93% | 4.8M -19.60% | 5.9M +27.08% | |
Total Long-Term Assets | 24.0M +345.15% | 5.4M +12.93% | 4.8M -19.60% | 5.9M +27.08% | |
Total Assets | 1.2B +71.72% | 691.2M +318.72% | 165.1M -46.11% | 306.3M -28.04% | |
Income Taxes Payable | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Short-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Current Liabilities | 50.6M +19.80% | 42.3M -17.30% | 51.1M +81.91% | 28.1M -2.21% | |
Total Long-Term Debt | 148.9M N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Long-Term Liabilities | 164.2M +758.00% | 19.1M -15.67% | 22.7M -12.28% | 25.9M -9.99% | |
Total Liabilities | 214.8M +249.91% | 61.4M -16.80% | 73.8M +36.75% | 54.0M -6.10% | |
Retained Earnings | -1.4B +46.97% | -949.9M +50.18% | -632.5M +59.49% | -396.6M +73.57% | |
Total Stockholders Equity | 972.1M +54.35% | 629.8M +589.92% | 91.3M -63.83% | 252.4M -31.46% | |
Total Shares Outstanding | 165.0M +61.21% | 102.3M +66.46% | 61.5M +10.48% | 55.6M +7.89% | |
Cash Flow | |||||
Cash from Operating Activities | -403.2M +37.91% | -292.4M +55.38% | -188.2M +22.46% | -153.6M +28.51% | |
Capital Expenditures | 1.9M -19.19% | 2.4M +225.93% | 729,000 -76.23% | 3.1M -15.23% | |
Cash from Investing Activities | -28.8M -85.91% | -204.1M -344.96% | 83.3M -4.46% | 87.2M +163.24% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 890.3M +9.93% | 809.9M +1,390.92% | 54.3M +45.28% | 37.4M -76.31% | |
Financials Ratio | |||||
Gross Margin | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Operating Margin | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Return on Assets | -47.52% -35.91% | -74.14% -25.94% | -100.10% +117.94% | -45.93% +19.83% | |
Return on Equity | -55.71% -36.72% | -88.03% -35.89% | -137.31% +153.45% | -54.18% +28.93% | |
Revenue Growth | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Current Ratio | 22.25 +42.64% | 15.60 +516.17% | 2.53 -73.22% | 9.46 -28.97% | |
Cash Ratio | 17.65 +71.25% | 10.30 +332.89% | 2.38 -61.16% | 6.13 -12.34% | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow